Related Experiment Video
Updated: Oct 30, 2025

A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
Photobiomodulation Therapy as a Possible New Approach in COVID-19: A Systematic Review
Brenda Thaynne Lima de Matos1, Daniela Vieira Buchaim2,3, Karina Torres Pomini1,2
1Department of Biological Sciences, Bauru School of Dentistry (FOB/USP), University of São Paulo, Bauru 17012-901, SP, Brazil.
Abstract:
COVID-19 is a viral disease characterized as a pandemic by the World Health Organization in March 2020. Since then, researchers from all over the world have been looking for ways to fight this disease. Many cases of complications arise from insufficient immune responses due to low immunity, with intense release of pro-inflammatory cytokines that can damage the structure of organs such as the lung. Thus, the hypothesis arises that photobiomodulation therapy (PBMT) with the use of a low-level laser (LLLT) may be an ally approach to patients with COVID-19 since it is effective for increasing immunity, helping tissue repair, and reducing pro-inflammatory cytokines. This systematic review was performed with the use of PubMed/MEDLINE, Web of Science, Scopus and Google Scholar databases with the following keywords: "low-level laser therapy OR photobiomodulation therapy AND COVID-19". The inclusion criteria were complete articles published from January 2020 to January 2021 in English. The exclusion criteria were other languages, editorials, reviews, brief communications, letters to the editor, comments, conference abstracts, and articles that did not provide the full text. The bibliographic search found 18 articles in the Pubmed/MEDLINE database, 118 articles on the Web of Science, 23 articles on Scopus, and 853 articles on Google Scholar. Ten articles were included for qualitative synthesis, of which four commentary articles discussed the pathogenesis and the effect of PBMT in COVID-19. Two in vitro and lab experiments showed the effect of PBMT on prevention of thrombosis and positive results in wound healing during viral infection, using the intravascular irradiation (ILIB) associated with Phthalomethyl D. Two case reports showed PBMT improved the respiratory indexes, radiological findings, and inflammatory markers in severe COVID-19 patients. One case series reported the clinical improvement after PBMT on 14 acute COVID-19 patients, rehabilitation on 24 patients, and as a preventive treatment on 70 people. One clinical trial of 30 patients with severe COVID-19 who require invasive mechanical ventilation, showed PBMT-static magnetic field was not statistically different from placebo for the length of stay in the Intensive Care Unit, but improved diaphragm muscle function and ventilation and decreased the inflammatory markers. This review suggests that PBMT may have a positive role in treatment of COVID-19. Still, the necessity for more clinical trials remains in this field and there is not sufficient research evidence regarding the effects of PBMT and COVID-19 disease, and there is a large gap.
Insights
Photobiomodulation therapy (PBMT) may aid COVID-19 patients by boosting immunity and reducing inflammation. Further clinical trials are needed to confirm PBMT
Area of Science:
- Medical Science
- Immunology
- Virology
Background:
- COVID-19 pandemic declared in March 2020.
- Complications often stem from weakened immune responses and excessive inflammation.
- Photobiomodulation therapy (PBMT) is explored for its potential to modulate immunity and aid tissue repair.
Purpose of the Study:
- To systematically review existing literature on the efficacy of PBMT for COVID-19 patients.
- To assess PBMT's potential role in managing COVID-19 symptoms and complications.
- To identify research gaps and the need for further clinical investigation.
Main Methods:
- Systematic literature search of PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar.
- Keywords used: "low-level laser therapy OR photobiomodulation therapy AND COVID-19".
- Inclusion criteria: Full-text English articles from Jan 2020 to Jan 2021; exclusion of non-full-text, reviews, and other non-primary research formats.
Main Results:
- Ten articles were included for qualitative synthesis.
- Commentaries discussed PBMT's role in COVID-19 pathogenesis.
- In vitro studies showed PBMT's potential in thrombosis prevention and wound healing.
- Case reports and series indicated PBMT improved respiratory and inflammatory markers in COVID-19 patients.
- One clinical trial showed PBMT improved diaphragm function and ventilation despite no significant difference in ICU stay.
Conclusions:
- PBMT shows promise as an adjunctive therapy for COVID-19.
- Evidence suggests PBMT may improve immune response, tissue repair, and reduce inflammation.
- More rigorous clinical trials are necessary to establish definitive evidence for PBMT in COVID-19 treatment.

